Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated April 07, 2025, titled "Sun Pharma introduces a novel class of drug, Fexuclue?(Fexuprazan) in India for treatment of Erosive Esophagitis ".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty 100 and 2.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma has launched Fexuclue (Fexuprazan), described as a novel class of drug, in India for the treatment of Erosive Esophagitis (a condition caused by acid reflux damaging the esophagus). Fexuprazan is a potassium-competitive acid blocker (PCAB), a new mechanism compared to traditional PPIs. The launch expands Sun Pharma's gastroenterology portfolio and adds a differentiated therapy to the Indian market. No revenue impact or financial guidance was provided in the announcement.
Positive for the company's domestic gastrointestinal portfolio and could support gradual revenue growth in the GI segment, though no immediate material impact on financials has been indicated.